On October 9–10, 2025, in Almaty and the Zhambyl Region, deputies of the Committee on International Affairs, Defense, and Security of the Mazhilis of the Parliament of the Republic of Kazakhstan held meetings with the subsidiary organizations of the National Holding “QazBioPharm.”

The delegation included Chair of the Committee Aigul Kuspan, deputies Olzhas Kuspekovand Maxim Rozhin, as well as Head of the Sector of the Committee’s Operations Department Kuanish Abenova. The delegation was accompanied by Ergali Abdurayimov, General Director of QazBioPharm National Holding JSC, and Aralbek Rsaliev, Deputy General Director for Science and Technology.

The purpose of the visit was to familiarize the deputies with the activities of the country’s leading research and production organizations that ensure biological safety, as well as to discuss current issues and prospects for the development of the sector.

The main venue of the meeting was the OtarBioPharm Biopharmaceutical Plant, operating under the Research Institute for Biological Safety Problems. During the visit, the deputies became acquainted with the activities of these organizations, toured production facilities and laboratories, and reviewed the process of vaccine and immunobiological product manufacturing. Special attention was given to the second production complex — the Workshop for the Production of Biologically Active Pharmaceutical Substances.

Committee Chair Aigul Kuspan emphasized the importance of developing domestic production and noted that such enterprises play a key role in ensuring Kazakhstan’s biological safety.

The delegation’s work continued the following day in Almaty, where the deputies visited the Masgut Aikimbayev National Scientific Center for Especially Dangerous Infections and the Kazakh Research Veterinary Institute. During the visit, the parliamentarians learned about ongoing research, laboratory capabilities, and projects aimed at preventing and monitoring especially dangerous infections.

The deputies highly appreciated the potential of QazBioPharm’s organizations and expressed gratitude to the staff for their high level of scientific and production performance. In turn, QazBioPharm’s management presented proposals to improve the regulatory framework and strengthen the scientific infrastructure in the field of biological safety.

Reference:
QazBioPharm National Holding JSC is Kazakhstan’s leading center for pharmaceutical science and innovation. The Holding’s activities are aimed at ensuring biological safety, developing biopharmaceutical production, conducting scientific research, and building a national knowledge base in the fields of healthcare and veterinary science.

QazBioPharm scientists are the developers of QazVac, Kazakhstan’s first COVID-19 vaccine — a landmark achievement demonstrating the country’s high scientific and technological potential.